Exploring the mechanisms of Jintiange capsules in OA treatment through miRNA-214-3p modulation in SMSC-ExosOA
Background:Osteoarthritis(OA)is a prevalent,chronic joint disease.Jintiange capsules(JTG),approved by the State Food and Drug Administration of China for orthopedic diseases,have shown noticeable benefits in treating chronic conditions through traditional Chinese medicine.Synovial mesenchymal stem cell-derived exosomes(SMSC-Exos)can modulate articular chondrocytes(ACs),but how pharmacological agents alter miRNA content in SMSC-Exos and influence ACs remains unclear.Methods:OA was induced in rats using type II collagenase,followed by a 30-day JTG regimen.Therapeutic efficacy was assessed by weight-bearing and mechanical allodynia tests,micro-CT,and Safranin-Fast Green staining.Differential miRNAs after JTG treatment were profiled by transcriptome analysis.JTG constituents were characterized via UPLC-Q-TOF-MS,and core targets/pathways were predicted by network pharmacology.Exosomes from JTG-treated SMSCs(SMSC-JTG-Exos)were tested in vitro on ACs to evaluate cell activity,migration,apoptosis,and key pathway gene/protein expression.Results:JTG ameliorated OA phenotypes in vivo.Transcriptomics identified nine miRNAs differentially expressed after JTG treatment.Integrating chemical profiling with network pharmacology highlighted ten core genes and implicated the rheumatoid arthritis signaling pathway,centering on miRNA-214-3p regulation.In vitro,SMSC-JTG-Exos enhanced ACs activity and migration,reduced apoptosis,and down-regulated related protein expression.Conclusion:JTG alleviates OA,at least in part,by up-regulating miRNA-214-3p in SMSC-Exos,which enhances ACs viability and suppresses apoptosis.The underlying mechanism likely involves modulation of the rheumatoid arthritis signaling pathway,suggesting an exosome-miRNAmediated route by which JTG exerts chondroprotective effects.
Zhi-Chao Wang;Fei Luan;Ya-Jun Shi;Xiao-Fei Zhang;Dong-Yan Guo;Bing-Tao Zhai;Liang Feng;Yi Dai;Jing Li;Jun-Bo Zou;Pu-Wei Yuan
School of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaSchool of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaSchool of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaSchool of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaSchool of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaSchool of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaSchool of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 211198,ChinaThe First Clinical Medical College,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaXi’an Jinhua Pharmaceutical Factory,Jinhua Enterprise(Group)Co.,Ltd.,Xi’an 710000,ChinaSchool of Pharmacy,Shaanxi University of Chinese Medicine,Xianyang 712046,ChinaThe First Clinical Medical College,Shaanxi University of Chinese Medicine,Xianyang 712046,China
医药卫生
osteoarthritisJintiange capsulesmiRNA-214-3psynovial mesenchymal stem cell Exostranscriptome sequencingUPLC-Q-TOF-MS
《Traditional Medicine Research》 2026 (7)
P.60-76,17
supported by the Science and Technology Innovative Talent Program of Shaanxi University of Chinese Medicine(No.2024-CXTD-03)the Key Research&Development Program of Shaanxi Provincial Department of Science and Technology(No.2024CY-JJQ-36,2024CY-JJQ-78)the National Young Qihuang Scholars Training Project(No.256(2022))the Young and Middle-Aged Scientific Research and Innovation Team of the Shaanxi Provincial Administration of Traditional Chinese Medicine(No.2022-SLRH-LJ-001)the Science and Technology Innovative Team Project of Shaanxi Administration of Traditional Chinese Medicine(No.2025-CXTD-02).
评论